04
окт
Kurtai Atlasi Tochiki 2017 Rating: 5,0/5 74 votes
• Shen, Sipeng; Shi, Qianwen; Bai, Jianling; Li, Jin; Qin, Shukui; Yu, Hao; Chen, Feng 2017-01-01 Apatinib is reported to significantly improve the overall survival (OS) of patients with advanced gastric cancer who have previously failed second-line chemotherapy. However, it is not well understood whether apatinib acts by improving progression or by prolonging post-progression survival. Here, based on phase III clinical trial data, the mediating effect of apatinib on patient overall survival was systematically quantified, through progression-free survival (PFS), post-progression survival (PPS), and the disease control rate (DCR).
PFS was the primary mediator of the association between apatinib treatment and OS, with an indirect-effect mean survival time ratio of 1.63 (95%CI 1.35-1.97), which mediated 93.5% of the treatment effect. The DCR was also a significant mediator among secondary efficacy endpoints, and had an indirect-effect mean survival time ratio of 1.47 (95%CI 1.20-1.79, 50.9% mediated). Both primary and other targets of the DCR had similar results. The results indicated that apatinib treatment prolongs progression-free survival rather than post-progression survival, and in turn, leads to improved overall survival. Additionally, our study highlights the value of mediation analysis in clinical trials in providing additional information to build upon traditional primary analysis.
PMID:27793017 • Huang, Lihong; Wei, Yongyue; Shen, Sipeng; Shi, Qianwen; Bai, Jianling; Li, Jin; Qin, Shukui; Yu, Hao; Chen, Feng 2017-04-25 Apatinib is reported to significantly improve the overall survival (OS) of patients with advanced gastric cancer who have previously failed second-line chemotherapy. However, it is not well understood whether apatinib acts by improving progression or by prolonging post-progression survival. Here, based on phase III clinical trial data, the mediating effect of apatinib on patient overall survival was systematically quantified, through progression-free survival (PFS), post-progression survival (PPS), and the disease control rate (DCR). PFS was the primary mediator of the association between apatinib treatment and OS, with an indirect-effect mean survival time ratio of 1.63 (95%CI 1.35-1.97), which mediated 93.5% of the treatment effect.
The DCR was also a significant mediator among secondary efficacy endpoints, and had an indirect-effect mean survival time ratio of 1.47 (95%CI 1.20-1.79, 50.9% mediated). Both primary and other targets of the DCR had similar results. The results indicated that apatinib treatment prolongs progression-free survival rather than post-progression survival, and in turn, leads to improved overall survival. Additionally, our study highlights the value of mediation analysis in clinical trials in providing additional information to build upon traditional primary analysis. • Phipps, Amanda I.; Limburg, Paul J.; Baron, John A.; Burnett-Hartman, Andrea N.; Weisenberger, Daniel J.; Laird, Peter W.; Sinicrope, Frank A.; Rosty, Christophe; Buchanan, Daniel D.; Potter, John D.; Newcomb, Polly A.
Cracked software for launch x431 If this is your first visit, be sure to check out the FAQ by clicking the link above. You may have to register before you can post: click the register link above to proceed. Offer you the software for ALL car brands to Launch x431 adapters (EasyDiag 2.0, IDIAG, DIAGUN III, ICarScan, GOLO, DBScar, V, V+, V+(2016), V(2016), Pro, PR. Skip navigation Sign in. Launch x431 cracked software. Autodiagnosticobd Launch x431-iv-software-download-update-manual • 1. Launch X431 software update instruction 1. Download software 1) Log in www.dbscar.com www.dbscar.com Log in 2) Click “Log in” at the upper right corner, input Login name and password. Launch x431 Diagun Last Software Cracked Last Cracked software for x431 Diagun, It will only work on x431 Diagun china Clone, Note: Don't try to format your card replace only the files in gag/vehicles/xxx Pt version, After i will add english version.
Popular Posts
• Shen, Sipeng; Shi, Qianwen; Bai, Jianling; Li, Jin; Qin, Shukui; Yu, Hao; Chen, Feng 2017-01-01 Apatinib is reported to significantly improve the overall survival (OS) of patients with advanced gastric cancer who have previously failed second-line chemotherapy. However, it is not well understood whether apatinib acts by improving progression or by prolonging post-progression survival. Here, based on phase III clinical trial data, the mediating effect of apatinib on patient overall survival was systematically quantified, through progression-free survival (PFS), post-progression survival (PPS), and the disease control rate (DCR).
PFS was the primary mediator of the association between apatinib treatment and OS, with an indirect-effect mean survival time ratio of 1.63 (95%CI 1.35-1.97), which mediated 93.5% of the treatment effect. The DCR was also a significant mediator among secondary efficacy endpoints, and had an indirect-effect mean survival time ratio of 1.47 (95%CI 1.20-1.79, 50.9% mediated). Both primary and other targets of the DCR had similar results. The results indicated that apatinib treatment prolongs progression-free survival rather than post-progression survival, and in turn, leads to improved overall survival. Additionally, our study highlights the value of mediation analysis in clinical trials in providing additional information to build upon traditional primary analysis.
PMID:27793017 • Huang, Lihong; Wei, Yongyue; Shen, Sipeng; Shi, Qianwen; Bai, Jianling; Li, Jin; Qin, Shukui; Yu, Hao; Chen, Feng 2017-04-25 Apatinib is reported to significantly improve the overall survival (OS) of patients with advanced gastric cancer who have previously failed second-line chemotherapy. However, it is not well understood whether apatinib acts by improving progression or by prolonging post-progression survival. Here, based on phase III clinical trial data, the mediating effect of apatinib on patient overall survival was systematically quantified, through progression-free survival (PFS), post-progression survival (PPS), and the disease control rate (DCR). PFS was the primary mediator of the association between apatinib treatment and OS, with an indirect-effect mean survival time ratio of 1.63 (95%CI 1.35-1.97), which mediated 93.5% of the treatment effect.
The DCR was also a significant mediator among secondary efficacy endpoints, and had an indirect-effect mean survival time ratio of 1.47 (95%CI 1.20-1.79, 50.9% mediated). Both primary and other targets of the DCR had similar results. The results indicated that apatinib treatment prolongs progression-free survival rather than post-progression survival, and in turn, leads to improved overall survival. Additionally, our study highlights the value of mediation analysis in clinical trials in providing additional information to build upon traditional primary analysis. • Phipps, Amanda I.; Limburg, Paul J.; Baron, John A.; Burnett-Hartman, Andrea N.; Weisenberger, Daniel J.; Laird, Peter W.; Sinicrope, Frank A.; Rosty, Christophe; Buchanan, Daniel D.; Potter, John D.; Newcomb, Polly A.
Cracked software for launch x431 If this is your first visit, be sure to check out the FAQ by clicking the link above. You may have to register before you can post: click the register link above to proceed. Offer you the software for ALL car brands to Launch x431 adapters (EasyDiag 2.0, IDIAG, DIAGUN III, ICarScan, GOLO, DBScar, V, V+, V+(2016), V(2016), Pro, PR. Skip navigation Sign in. Launch x431 cracked software. Autodiagnosticobd Launch x431-iv-software-download-update-manual • 1. Launch X431 software update instruction 1. Download software 1) Log in www.dbscar.com www.dbscar.com Log in 2) Click “Log in” at the upper right corner, input Login name and password. Launch x431 Diagun Last Software Cracked Last Cracked software for x431 Diagun, It will only work on x431 Diagun china Clone, Note: Don't try to format your card replace only the files in gag/vehicles/xxx Pt version, After i will add english version.
...">Kurtai Atlasi Tochiki 2017(04.10.2018)• Shen, Sipeng; Shi, Qianwen; Bai, Jianling; Li, Jin; Qin, Shukui; Yu, Hao; Chen, Feng 2017-01-01 Apatinib is reported to significantly improve the overall survival (OS) of patients with advanced gastric cancer who have previously failed second-line chemotherapy. However, it is not well understood whether apatinib acts by improving progression or by prolonging post-progression survival. Here, based on phase III clinical trial data, the mediating effect of apatinib on patient overall survival was systematically quantified, through progression-free survival (PFS), post-progression survival (PPS), and the disease control rate (DCR).
PFS was the primary mediator of the association between apatinib treatment and OS, with an indirect-effect mean survival time ratio of 1.63 (95%CI 1.35-1.97), which mediated 93.5% of the treatment effect. The DCR was also a significant mediator among secondary efficacy endpoints, and had an indirect-effect mean survival time ratio of 1.47 (95%CI 1.20-1.79, 50.9% mediated). Both primary and other targets of the DCR had similar results. The results indicated that apatinib treatment prolongs progression-free survival rather than post-progression survival, and in turn, leads to improved overall survival. Additionally, our study highlights the value of mediation analysis in clinical trials in providing additional information to build upon traditional primary analysis.
PMID:27793017 • Huang, Lihong; Wei, Yongyue; Shen, Sipeng; Shi, Qianwen; Bai, Jianling; Li, Jin; Qin, Shukui; Yu, Hao; Chen, Feng 2017-04-25 Apatinib is reported to significantly improve the overall survival (OS) of patients with advanced gastric cancer who have previously failed second-line chemotherapy. However, it is not well understood whether apatinib acts by improving progression or by prolonging post-progression survival. Here, based on phase III clinical trial data, the mediating effect of apatinib on patient overall survival was systematically quantified, through progression-free survival (PFS), post-progression survival (PPS), and the disease control rate (DCR). PFS was the primary mediator of the association between apatinib treatment and OS, with an indirect-effect mean survival time ratio of 1.63 (95%CI 1.35-1.97), which mediated 93.5% of the treatment effect.
The DCR was also a significant mediator among secondary efficacy endpoints, and had an indirect-effect mean survival time ratio of 1.47 (95%CI 1.20-1.79, 50.9% mediated). Both primary and other targets of the DCR had similar results. The results indicated that apatinib treatment prolongs progression-free survival rather than post-progression survival, and in turn, leads to improved overall survival. Additionally, our study highlights the value of mediation analysis in clinical trials in providing additional information to build upon traditional primary analysis. • Phipps, Amanda I.; Limburg, Paul J.; Baron, John A.; Burnett-Hartman, Andrea N.; Weisenberger, Daniel J.; Laird, Peter W.; Sinicrope, Frank A.; Rosty, Christophe; Buchanan, Daniel D.; Potter, John D.; Newcomb, Polly A.
Cracked software for launch x431 If this is your first visit, be sure to check out the FAQ by clicking the link above. You may have to register before you can post: click the register link above to proceed. Offer you the software for ALL car brands to Launch x431 adapters (EasyDiag 2.0, IDIAG, DIAGUN III, ICarScan, GOLO, DBScar, V, V+, V+(2016), V(2016), Pro, PR. Skip navigation Sign in. Launch x431 cracked software. Autodiagnosticobd Launch x431-iv-software-download-update-manual • 1. Launch X431 software update instruction 1. Download software 1) Log in www.dbscar.com www.dbscar.com Log in 2) Click “Log in” at the upper right corner, input Login name and password. Launch x431 Diagun Last Software Cracked Last Cracked software for x431 Diagun, It will only work on x431 Diagun china Clone, Note: Don't try to format your card replace only the files in gag/vehicles/xxx Pt version, After i will add english version.
...">Kurtai Atlasi Tochiki 2017(04.10.2018)Most Viewed Pages
© 2019 Kurtai Atlasi Tochiki 2017.